Apr 21, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks in Queue: bluebird bio Inc (NASDAQ:BLUE), Ariad Pharmaceuticals Inc (NASDAQ:ARIA), Stem Cells Inc (NASDAQ:STEM)

Stocks in Queue: bluebird bio Inc (NASDAQ:BLUE), Ariad Pharmaceuticals Inc (NASDAQ:ARIA), Stem Cells Inc (NASDAQ:STEM)

bluebird bio Inc (NASDAQ:BLUE) stock is at $44.31, down -7.15 percent from its previous close of $47.72. The stock opened the session at $49.79 and touched its highest price point at $49.97. The company’s stock’s lowest price point for the session stood at $43.07. Its yesterday’s volume was 3.06 million shares in comparison to its usual trading volume of 1.29 million shares.

bluebird bio Inc (NASDAQ:BLUE) on February 24, 2016 reported financial results for the fourth quarter and full year ended December 31, 2015.

Fourth Quarter and Full Year 2015 Financial Results and Financial Guidance

  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2015 were $865.8 million, compared to $492.0 million as of December 31, 2014, an increase of $373.8 million, which was primarily driven by the June 2015 equity financing partially offset by cash used to fund operations.
  • Revenues: Collaboration revenue was $1.5 million for the fourth quarter of 2015 and $14.1 million for the year ended December 31, 2015, compared to $6.3 million and $25.0 million in the comparable periods in 2014. The decrease is a result of an amendment to our collaboration agreement with Celgene in the second quarter of 2015.
  • R&D Expenses: Research and development expenses were $35.7 million for the fourth quarter of 2015 and $134.0 million for the year ended December 31, 2015, compared to $20.5 million and $62.6 million for the comparable periods in 2014. The increase in research and development expenses was primarily attributable to increased employee compensation expense due to increased headcount, in-licensing milestones and fees, and manufacturing and clinical trial-related costs to support our advancing pipeline.
  • G&A Expenses: General and administrative expenses were $14.4 million for the fourth quarter of 2015 and $46.2 million for the year ended December 31, 2015, compared to $5.3 million and $23.2 million for the comparable periods in 2014. The increase in general and administrative expenses was primarily attributable to increased employee compensation expense due to increased headcount, and consulting and facilities-related costs to support our overall growth.
  • Net Loss: Net loss was $47.3 million for the fourth quarter of 2015 and $166.8 million for the year ended December 31, 2015, compared to net loss of $19.5 million and $48.7 million for the comparable periods in 2014.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) stock is at $7.28, up +1.39 percent from its previous close of $7.18. Its yesterday’s volume was 2.95 million shares in comparison to its usual trading volume of 3.87 million shares. Previous 5 days graph demonstrated a positive move of 12.17%. Its quarterly performance remained green with the percentage of 33.21, while its year to date performance showed that the stock advanced overall 14.83%.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) on April 15, 2016 announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the brigatinib safety profile and pharmacokinetics (PK) from all patients treated in the trial, with a focus on brigatinib clinical activity in patients with ALK+ NSCLC, including those with intracranial CNS metastases at study entry. The report also details overall survival outcomes of patients in the study.

The data presented at ELCC include pharmacokinetics and safety analyses on all patients in the trial (n=137) and efficacy analyses on patients with ALK+ NSCLC (n=79). The presentation is based on patient data as of February 2015 with a median time on treatment for ALK+ NSCLC patients of 12.6 months (range, 0.03 – 35.5+ months). Patient enrollment in the trial is complete, with the last patient enrolled in July 2014. The primary endpoint in the Phase 2 portion of the trial is overall response rate. Secondary endpoints include safety and tolerability, pharmacokinetic parameters, progression free survival, and overall survival.

Stem Cells Inc (NASDAQ:STEM) traded in the range of $0.26 and $0.28 in its previous trading session. The stock recorded the volume of 2.95 million shares so far, in comparison its average daily trading volume of 2.19 million shares. Company’s year to date performance remained as it lost almost -40.77%. The stock opened at $0.28 and its closing price for the day was $0.264, up +1.35 percent from its previous close.

Stem Cells Inc (NASDAQ:STEM) on March 30, 2016 announced the company’s ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) was featured in an article published in The Downey Patriot.

The Phase II Pathway Study, titled “Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury,” will evaluate the safety and efficacy of transplanting the Company’s proprietary human neural stem cells (HuCNS-SC® cells) into patients with traumatic injury in the cervical region of the spinal cord. Conducted as a randomized, controlled, single-blinded study, the trial will measure efficacy by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms and shoulders. The trial will enroll approximately 52 subjects in three cohorts.  Enrollment in the first cohort of six subjects has been completed.  The Company is actively enrolling 40 patients in cohort II.

 

Comments are closed.